A Phase 2, Randomized, Open Label Study Of Figitumumab (CP-751,871) Plus Cisplatin (Or Carboplatin) And Etoposide, Versus Cisplatin (Or Carboplatin) And Etoposide Alone, As First Line Treatment In Patients With Extensive Stage Disease Small Cell Lung Cancer
The study prematurely discontinued on January 26, 2011 due to slow enrollment. It should be
noted that safety concerns have not been seen in this study and have not factored into this
decision.
Interventional
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression-Free Survival (PFS)
Median time from the first dose of study treatment to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first. PFS time (days) = [event (progression or death) date or censor date - date of randomization + 1].
Baseline, every 2nd cycle (between Day 15-21, 1 cycle = 21 days) starting with Cycle 2 until disease progression, at the end of treatment visit (if more than 28 days have passed since last evaluation); and every 6 weeks until disease progression
No
Pfizer CT.gov Call Center
Study Director
Pfizer
United States: Food and Drug Administration
A4021032
NCT00977561
April 2010
October 2011
Name | Location |
---|---|
Pfizer Investigational Site | Richmond, Virginia 23249 |
Pfizer Investigational Site | Federal Way, Washington 98003 |
Pfizer Investigational Site | Columbia, Missouri 65201 |
Pfizer Investigational Site | Asheville, North Carolina 28801 |
Pfizer Investigational Site | Eugene, Oregon 97401 |
Pfizer Investigational Site | Kingston, Pennsylvania 18704-5535 |
Pfizer Investigational Site | Shreveport, Louisiana 71103 |
Pfizer Investigational Site | Livingston, New Jersey 07039 |
Pfizer Investigational Site | Washington, District of Columbia 20007-2197 |